Login
$TEVA
$42.57 +$0.00 (0.0%) After hours

$TEVA 8-K SEC Filings

Filed On Filing
03 Nov 2026 8-K: Results of Operations and Financial Condition

Teva’s Pivot to Growth Strategy Delivers 33% Growth Across Key Innovative Brands; Raises 2026 Outlook for AUSTEDO®, AJOVY® and UZEDY®; Delivers Substantial Gross Margin Expansion

29 Oct 2026 8-K: Departure/Election of Directors or Officers; Compensation

On October 27, 2026, at a meeting of the Board of Directors (the “Board”) of Teva Pharmaceutical Industries Ltd. (“Teva” or the “Company”), the Board elected Dr. David J. Brailer to serve as a member of the Board, effective November 3, 2...

16 Sep 2026 8-K: Entry into a Material Definitive Agreement; Creation of a Direct Financial Obligation

Creating the series of Securities (as defined herein) designated

14 Sep 2026 8-K: Other Events

On September 14, 2026, Teva Pharmaceutical Industries Ltd. (the “Company”) began trading its ordinary shares on the New York Stock Exchange, in lieu of its American depositary shares (“ADSs”), under the same ticker symbol under which the...

11 Sep 2026 8-K: Regulation FD Disclosure; Other Events

To: the other Euro Underwriters (as defined herein) listed in Part A of Schedule I hereto;

03 Sep 2026 8-K: Other Events

Teva Pharmaceutical Industries Limited (“Teva” or the “Company”) is filing this Exhibit 99.1 to recast historical segment information as set forth in the Company’s Annual Report on Form

03 Sep 2026 8-K: Material Modification to Rights of Security Holders

AMENDMENT NO. 1 TO SECOND AMENDED AND RESTATED DEPOSIT AGREEMENT, dated as of August 31, 2026 (“Amendment No. 1”), by and among Teva Pharmaceutical Industries Limited, a company incorporated under the laws of the State of Israel, and its...

29 Jul 2026 8-K: Results of Operations and Financial Condition

Teva Delivers Strong Q2 Results and Raises Outlook for All Three Key Innovative Brands, Reflecting Continued Execution of Its Pivot to Growth Strategy

28 May 2026 8-K: Submission of Matters to a Vote of Security Holders

Teva Pharmaceutical Industries Limited (“Teva” or the “Company”) held its Annual Meeting on May 28, 2026 (the “Annual Meeting”). The following is a summary of the matters voted on at the meeting.

29 Apr 2026 8-K: Results of Operations and Financial Condition; Regulation FD Disclosure

For an accessible version of this Press Release, please visit www.tevapharm.com

28 Jan 2026 8-K: Results of Operations and Financial Condition

Teva Innovative Portfolio and Consistent Execution of Pivot to Growth Strategy Deliver Third Consecutive Year of Growth; Pipeline Positioned to Unlock Significant Value Potential

12 Jan 2026 8-K: Results of Operations and Financial Condition

Teva to Present at the 44th Annual J.P. Morgan Healthcare Conference: Pivot to Growth Strategy Delivering Growth and Transforming through Innovation

11 Dec 2025 8-K: Entry into a Material Definitive Agreement; Creation of a Direct Financial Obligation

This AMENDMENT to the Senior Unsecured Sustainability-Linked Revolving Credit Agreement, dated as of December 10, 2025 (this “Amendment”), is made and entered into by and among TEVA PHARMACEUTICAL INDUSTRIES LIMITED, an Israeli company r...

05 Nov 2025 8-K: Results of Operations and Financial Condition

Teva's Innovative Portfolio Drives 11th Consecutive Quarter of Growth in Q3 2025; Increases 2025 Outlook for Austedo® and Non-GAAP EPS

30 Jul 2025 8-K: Results of Operations and Financial Condition

Teva's Innovative Portfolio Fuels 10th Consecutive Quarter of Growth in Q2 2025; Increases 2025 Revenue Outlook for Key Innovative Products and EPS, and Reaffirms All Other Components

05 Jun 2025 8-K: Submission of Matters to a Vote of Security Holders

Teva Pharmaceutical Industries Limited (“Teva” or the “Company”) held its Annual Meeting on June 5, 2025 (the “Annual Meeting”). The following is a summary of the matters voted on at the meeting.

28 May 2025 8-K: Entry into a Material Definitive Agreement; Creation of a Direct Financial Obligation

THIS INDENTURE, dated as of May 28, 2025, by and among Teva Pharmaceutical Finance Netherlands IV B.V., a private company with limited liability (besloten vennootschap met beperkte aansprakelijkheid), incorporated under Dutch law (the “I...

22 May 2025 8-K: Regulation FD Disclosure; Other Events

To: the other Euro Underwriters (as defined herein) listed in Part A of Schedule I hereto

07 May 2025 8-K: Results of Operations and Financial Condition

Teva Reports Ninth Consecutive Quarter of Growth in Q1 2025 With Key Innovative Medicines Growing ~40%; 2025 Profit Outlook Improved

29 Jan 2025 8-K: Results of Operations and Financial Condition

Teva Delivers Second Consecutive Year of Growth; Announces Strong Financial Results in Fourth Quarter and Full Year 2024, Led by Generics Performance and Innovative Portfolio Growth

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Premium Feature

This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.

Premium includes:

  • Unlimited historical financial data
  • Advanced analytics and insights
  • Priority support